MAIA Biotechnology secures funding for clinical trial of ateganosine

MAIA Biotechnology (MAIA) announced that net proceeds from its $33M public offering of common stock in March are expected to fully fund the company’s ongoing pivotal Phase 3 clinical trial of its lead investigational therapy, ateganosine, as a treatment for non-small cell lung cancer. Ateganosine is a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. The FDA has granted Fast Track designation for the drug in third line NSCLC treatment.